PUBLIC COMPANY
save$CGEMCullinan Therapeutics, Inc.
$CGEM15.51+6.74%Cambridge, MA, USupdated 1d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
- phase1A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- phase1CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- phase1A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
- phase1A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
- phase1A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
- phase2A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
- phase1CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
🐶 Hiring Signal
next earnings Nov 5, 2026
News
- Vertex’s latest autoimmune TCE play involves $28M upfront to AbCelleraAbCellera’s T-cell engager platform has reeled in a second client this summer, with Vertex paying $28 million upfront for a collaboration that will include autoimmune conditions.fiercebiotech · 2mo ago
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that